Home/Recalls/FDA-D-0527-2026
FDA DrugsClass II

Buprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx o...

Published: May 20, 2026Recall ID: D-0527-2026Category: drugsCountry: US

Reason for Recall / Hazard

Crystallization; identified as Buprenorphine free base

Product Description & Identification

Buprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only, Manufactured for: Endo USA, Malvern, PA 19855, NDC 42023-179-05.

Additional Source Details

FieldValue
CityRochester
StateMI
Openfda › Unii56W8MW3EN1
Openfda › Route › 1INTRAMUSCULAR
Openfda › Route › 2INTRAVENOUS
Openfda › Rxcui238129
Openfda › Spl id32a7af7e-3f90-4881-9075-473644237017
Openfda › Brand nameBUPRENORPHINE HYDROCHLORIDE
Openfda › Spl set id34767dda-ce52-4f98-a45f-bb5cee0cd5e6
Openfda › Package ndc42023-179-05
Openfda › Product ndc42023-179
Openfda › Generic nameBUPRENORPHINE HYDROCHLORIDE
Openfda › Product typeHUMAN PRESCRIPTION DRUG
Openfda › Substance nameBUPRENORPHINE HYDROCHLORIDE
Openfda › Manufacturer namePar Health USA, LLC
Openfda › Application numberANDA206586
Openfda › Is original packagertrue
Event id98610
Address 1870 Parkdale Rd
Code infoLot #: 84132, Exp 02/28/2027; 87693, Exp 03/31/2027
Postal code48307-1740
Report date20260520
Product typeDrugs
Product quantity34,293 vials
Reason for recallCrystallization; identified as Buprenorphine free base
Voluntary mandatedVoluntary: Firm initiated
Recall initiation date20260313
Initial firm notificationLetter
Center classification date20260511

Overview

  • Recalling FirmENDO USA, Inc.
  • StatusOngoing
  • Risk LevelClass II
  • DistributionUSA Nationwide
Official Agency Alert